Rosiglitazone-Associated Fractures in Type 2 Diabetes

Abstract

Further investigation into the risk factors and underlying pathophysiology for the increased fracture rate in women taking rosiglitazone is required to relate them to preclinical data and better understand the clinical implications of and possible interventions for these findings.